Clinical Edge Journal Scan

Dactylitis indicates a more severe disease phenotype in early PsA


 

Key clinical point: Presence of dactylitis independently confirmed more severe disease burden with higher swollen joint counts (SJC), C-reactive protein (CRP) levels, ultrasound-detected synovitis, and bone erosion in disease-modifying antirheumatic drug (DMARD)-naive patients with early psoriatic arthritis (PsA).

Major finding: Dactylitic vs. nondactylitic PsA was associated with a higher SJC ( P < .001) and CRP level ( P = .006) and a higher prevalence of ultrasound synovitis ( P < .001) and bone erosions ( P < .001). After excluding dactylitic digits, SJC was greater ( P = .002) and ultrasound-detected synovitis ( P < .001) and erosions ( P = .008) were more prevalent in dactylitic vs. nondactylitic PsA.

Study details: This study included 177 DMARD-naive patients with early PsA who were stratified by the presence or absence of dactylitis at baseline.

Disclosures: This study was funded by the National Institute for Health Research Leeds Biomedical Research Centre. The authors declared no conflict of interests.

Source: Dubash S et al. Ann Rheum Dis. 2021 (Dec 10). Doi: 10.1136/annrheumdis-2021-220964.

Recommended Reading

Clinical Edge Journal Scan Commentary: PsA December 2021
MDedge Rheumatology
Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indication
MDedge Rheumatology
New option for flares in pustular psoriasis
MDedge Rheumatology
Spesolimab speeds lesion clearance in generalized pustular psoriasis
MDedge Rheumatology
Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
MDedge Rheumatology
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
MDedge Rheumatology
Discontinuing TNF inhibitors may not be required in PsA patients receiving BNT162b2 SARS-CoV-2 vaccine
MDedge Rheumatology
PsA: Upadacitinib shows similar benefits as monotherapy or in combination with nbDMARDs
MDedge Rheumatology
Psoriatic arthritis management should target both clinical and biochemical inflammation
MDedge Rheumatology
Risankizumab shows promise in PsA patients with inadequate response to csDMARDs
MDedge Rheumatology